There is no research data on how long dasatinib tablets can be discontinued, and they are generally taken until the disease has progressed or the patient no longer tolerates the regimen. Relevant clinical studies have shown a median treatment duration of about 15 months for this drug. Dasatinib tablets are usually used for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic, accelerated, and acute phases who are resistant to, or intolerant of, imatinib mesylate. The duration of dosing is related to the condition and the patient’s physical fitness, and the time to discontinue the drug varies from person to person. Dasatinib Tablet use may be infected, sepsis, bone marrow suppression, lymphadenopathy, allergy, hypothyroidism, loss of appetite and other adverse reactions, allergy to the components of the product is prohibited for patients. It is recommended that patients use the drug strictly under the guidance of a physician, adjust the dosage of the drug in a timely manner according to the condition, and if it is necessary to use it simultaneously with other drugs, you can consult a physician in advance.